AQZELO Trademark

Trademark Overview


On Monday, March 14, 2022, a trademark application was filed for AQZELO with the United States Patent and Trademark Office. The USPTO has given the AQZELO trademark a serial number of 97310830. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Monday, August 19, 2024. This trademark is owned by Eli Lilly and Company. The AQZELO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascula...
aqzelo

General Information


Serial Number97310830
Word MarkAQZELO
Filing DateMonday, March 14, 2022
Status732 - THIRD EXTENSION - GRANTED
Status DateMonday, August 19, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 17, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, March 18, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Friday, March 18, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 17, 2022NEW APPLICATION ENTERED
Monday, December 12, 2022ASSIGNED TO EXAMINER
Wednesday, December 14, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 28, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 17, 2023PUBLISHED FOR OPPOSITION
Tuesday, January 17, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 14, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, February 19, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, August 15, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, August 15, 2023SOU EXTENSION 1 FILED
Tuesday, August 15, 2023SOU EXTENSION 1 GRANTED
Thursday, August 17, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 19, 2024SOU EXTENSION 2 FILED
Monday, February 19, 2024SOU EXTENSION 2 GRANTED
Monday, August 19, 2024SOU TEAS EXTENSION RECEIVED
Monday, August 19, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 19, 2024SOU EXTENSION 3 GRANTED
Monday, August 19, 2024SOU EXTENSION 3 FILED
Tuesday, February 20, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED